PL1718737T3 - Przeciwciała modyfikujące przebieg choroby nowotworowej - Google Patents

Przeciwciała modyfikujące przebieg choroby nowotworowej

Info

Publication number
PL1718737T3
PL1718737T3 PL05714544T PL05714544T PL1718737T3 PL 1718737 T3 PL1718737 T3 PL 1718737T3 PL 05714544 T PL05714544 T PL 05714544T PL 05714544 T PL05714544 T PL 05714544T PL 1718737 T3 PL1718737 T3 PL 1718737T3
Authority
PL
Poland
Prior art keywords
antibodies
cancer
disease modifying
cancerous disease
modifying antibodies
Prior art date
Application number
PL05714544T
Other languages
English (en)
Inventor
David S F Young
Susan E Hahn
Lisa M Cechetto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1718737T3 publication Critical patent/PL1718737T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL05714544T 2004-02-26 2005-02-28 Przeciwciała modyfikujące przebieg choroby nowotworowej PL1718737T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54866704P 2004-02-26 2004-02-26
EP05714544A EP1718737B1 (en) 2004-02-26 2005-02-28 Cancerous disease modifying antibodies
PCT/CA2005/000302 WO2005083064A1 (en) 2004-02-26 2005-02-28 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
PL1718737T3 true PL1718737T3 (pl) 2010-10-29

Family

ID=34911008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05714544T PL1718737T3 (pl) 2004-02-26 2005-02-28 Przeciwciała modyfikujące przebieg choroby nowotworowej

Country Status (15)

Country Link
US (1) US7399835B2 (pl)
EP (1) EP1718737B1 (pl)
JP (1) JP2008504227A (pl)
CN (1) CN1934246A (pl)
AT (1) ATE469220T1 (pl)
AU (1) AU2005217008A1 (pl)
CA (1) CA2557093A1 (pl)
DE (1) DE602005021459D1 (pl)
DK (1) DK1718737T3 (pl)
ES (1) ES2345260T3 (pl)
NZ (1) NZ549409A (pl)
PL (1) PL1718737T3 (pl)
PT (1) PT1718737E (pl)
SI (1) SI1718737T1 (pl)
WO (1) WO2005083064A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
KR20090101886A (ko) * 2006-11-13 2009-09-29 에프. 호프만-라 로슈 아게 암 질환 조절 항체
AU2008232260A1 (en) * 2007-03-26 2008-10-02 F. Hoffmann-La Roche Ag Cancer disease modifying antibody 010207-01 produced by hybridoma cell line AR51A630.3.
WO2009009881A1 (en) * 2007-07-16 2009-01-22 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (en) * 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
AU613590B2 (en) 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
WO1996000084A1 (en) 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
WO2003030831A2 (en) 2001-10-11 2003-04-17 Protein Design Labs, Inc. Treatment of prostate cancer by inhibitors of atp synthase
AU2003227148A1 (en) 2002-04-05 2003-10-27 Arius Research, Inc. Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
US20060140963A1 (en) 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59

Also Published As

Publication number Publication date
US20050191305A1 (en) 2005-09-01
PT1718737E (pt) 2010-08-09
NZ549409A (en) 2009-12-24
WO2005083064A1 (en) 2005-09-09
EP1718737B1 (en) 2010-05-26
CN1934246A (zh) 2007-03-21
US7399835B2 (en) 2008-07-15
DE602005021459D1 (de) 2010-07-08
JP2008504227A (ja) 2008-02-14
ATE469220T1 (de) 2010-06-15
AU2005217008A1 (en) 2005-09-09
SI1718737T1 (sl) 2010-09-30
DK1718737T3 (da) 2010-08-09
EP1718737A4 (en) 2007-03-28
ES2345260T3 (es) 2010-09-20
CA2557093A1 (en) 2005-09-09
EP1718737A1 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
PL1718737T3 (pl) Przeciwciała modyfikujące przebieg choroby nowotworowej
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
WO2004065422A3 (en) Cancerous disease modifying antibodies
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
EP1929034A4 (en) ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
WO2008058380A8 (en) Cancerous disease modifying antibodies
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
DK1360208T3 (da) Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas
WO2009094751A8 (en) An anti-cancer cytotoxic monoclonal antibody